Persistence of functional antibodies to group B streptococcal capsular polysaccharides following immunization with glycoconjugate vaccines

Vaccine

Volumn 30, Issue 28, 2012, Pages 4123-4126

  Edwards, Morven S ^a   Lane, Heidi J ^a   Hillier, Sharon L ^b,c   Rench, Marcia A ^a   Baker, Carol J ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Antibody; Durability; Glycoconjugate; Group B Streptococcus; Polysaccharide; Vaccine

Indexed keywords

BACTERIAL POLYSACCHARIDE; GLYCOCONJUGATE; IMMUNOGLOBULIN G; STREPTOCOCCUS VACCINE; TETANUS TOXOID;

ANTIBODY RESPONSE; ARTICLE; DRUG EFFECT; GROUP B STREPTOCOCCAL INFECTION; HUMAN; IMMUNIZATION; PHAGOCYTOSIS; PRIORITY JOURNAL; STREPTOCOCCUS AGALACTIAE;

ADULT; ANTIBODIES, BACTERIAL; BLOOD BACTERICIDAL ACTIVITY; HUMANS; IMMUNOGLOBULIN G; OPSONIN PROTEINS; PHAGOCYTOSIS; POLYSACCHARIDES, BACTERIAL; STREPTOCOCCAL VACCINES; STREPTOCOCCUS AGALACTIAE; TIME FACTORS; VACCINES, CONJUGATE;

EID: 84861716659     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.048     Document Type: Article

References (22)

1. Phares C.R., Lynfield R., Farley M.M., Mohle-Boetani J., Harrison L.H., Petit S., et al. Epidemiology of invasive group B streptococcal disease in the United States, 1999-2005. JAMA 2008, 299:2056-2065.
2. Centers for Disease Control and Prevention 2012. Active Bacterial Core Surveillance Report, Emerging Infections Program Network, Group B Streptococcus, 2010. Available via the internet: http://cdc.gov/abcs/reports-findings/survreports/gbs10.pdf.
3. Baker C.J., Kasper D.L. Correlation of maternal antibody deficiency with susceptibility to neonatal group B streptococcal infection. New England Journal of Medicine 1976, 294:753-756.
4. Baker C.J., Kasper D.L., Tager I.B., Paredes A., Alpert S., McCormack W.M., et al. Quantitative determination of antibody to capsular polysaccharide in infection with type III strains of group B Streptococcus. Journal of Clinical Investigation 1977, 59:810-818.
5. Baker C.J., Paoletti L.C., Wessels M.R., Guttormsen H.-K., Rench M.A., Hickman M.E., et al. Safety and immunogenicity of capsular polysaccharide-tetanus toxoid conjugate vaccines for group B streptococcal types Ia and Ib. Journal of Infectious Diseases 1999, 179:142-150.
6. Baker C.J., Rench M.A., Fernandez M., Paoletti L.C., Kasper D.L., Edwards M.S. Safety and immunogenicity of a bivalent group B streptococcal conjugate vaccine for serotypes II and III. Journal of Infectious Diseases 2003, 188:66-73.
7. Baker C.J., Rench M.A., McInnes P. Immunization of pregnant women with group B streptococcal type III capsular polysaccharide-tetanus toxoid conjugate vaccine. Vaccine 2003, 21:3468-3472.
8. Baker C.J., Rench M.A., Paoletti L.C., Edwards M.S. Dose-response to type V group B streptococcal polysaccharide-tetanus toxoid conjugate vaccine in healthy adults. Vaccine 2007, 25:55-63.
9. Baker C.J., Paoletti L.C., Rench M.A., Guttormsen H.-K., Edwards M.S., Kasper D.L. Immune response of healthy women to 2 different group B streptococcal type V capsular polysaccharide-protein conjugate vaccines. Journal of Infectious Diseases 2004, 189:1103-1112.
10. Palazzi D.L., Rench M.A., Edwards M.S., Baker C.J. Use of type V group B streptococcal conjugate vaccine in adults 65-85 years old. Journal of Infectious Diseases 2004, 190:558-564.
11. DEVANI. Vaccine against neonatal infections: Design of a vaccine to immunize neonates against GBS infections through a durable maternal response [accessed 5/1/2012 at]. http://www.devaniproject.org/.
12. Hillier S., Ferris D., Fine P., Ferrieri P., Edwards M., Carey V., et al. Women receiving group B Streptococcus serotype III tetanus toxoid (GBS III-TT) vaccine have reduced vaginal and rectal acquisition of GBS type III. Abstracts of the 47th Infectious Diseases Society of America Annual Meeting 2009, [abstract #186].
13. Hall M.A., Edwards M.S., Baker C.J. Complement and antibody participation in opsonophagocytosis of type IV and V group B streptococci. Infection and Immunity 1992, 60:5030-5035.
14. Lin F.-Y.C., Philips J.B., Azimi P.H., Weisman L.E., Clark P., Rhoads G.G., et al. Level of maternal antibody required to protect neonates against early-onset disease caused by group B Streptococcus type Ia: a multicenter, seroepidemiology study. Journal of Infectious Diseases 2001, 184:1022-1028.
15. Lin F.-Y.C., Weisman L.E., Azimi P.H., Philips J.B., Clark P., Regan J., et al. Level of maternal IgG anti-group B Streptococcus type III antibody correlated with protection of neonates against early-onset disease caused by this pathogen. Journal of Infectious Diseases 2004, 190:928-934.
16. Pollard A.J., Perrett K.P., Beverley P.C. Maintaining protection against invasive bacteria with protein-polysaccharide conjugate vaccines. Nature Reviews Immunology 2009, 9:213-220.
17. Snape M.D., Kelly D.F., Lewis S., Banner C., Kibwana L., Moore C.E., et al. Seroprotection against serogroup C meningococcal disease in adolescents in the United Kingdom: observational study. BMJ 2008, 336:1487-1491.
18. Artz A.S., Ershler W.B., Longo D.L. Pneumococcal vaccination and revaccination of older adults. Clinical Microbiology Reviews 2003, 16:308-318.
19. Campbell J.R., Hillier S.L., Krohn M.A., Ferrieri P., Zaleznik D.F., Baker C.J. Group B streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstetrics and Gynecology 2000, 96:498-503.
20. Madhi S.A., Violari A., Klugman K.P., Lin G., McIntyre J.A., von Gottberg A., et al. Inferior quantitative and qualitative immune responses to pneumococcal conjugate vaccine in infants with nasopharyngeal colonization by Streptococcus pneumoniae during the primary series of immunization. Vaccine 2011, 29:6994-7001.
21. Simell B., Vuorela A., Ekström N., Palmu A., Reunanen A., Meri S., et al. Aging reduces the functionality of anti-pneumococcal antibodies and the killing of Streptococcus pneumoniae by neutrophil phagocytosis. Vaccine 2011, 29:1929-1934.
22. Romero-Steiner S., Musher D.M., Cetron M.S., Pais L.B., Groover J.E., Fiore A.E., et al. Reduction in functional antibody activity against Streptococcus pneumoniae in vaccinated elderly individuals highly correlates with decreased IgG antibody avidity. Clinical Infectious Diseases 1999, 29:281-288.